1. Home
  2. |Insights
  3. |Mere Demonstration At A Trade Show Does Not Constitute Infringing Use

Mere Demonstration At A Trade Show Does Not Constitute Infringing Use

Client Alert | 1 min read | 09.11.08

For purposes of establishing personal jurisdiction, mere demonstration of an allegedly infringing device at a trade show does not constitute "use" under the patent laws, a Federal Circuit panel concludes in Medical Solutions, Inc. v. C Change Surgical LLC (No. 2007-1163; September 9, 2008).

Defendant C Change Surgical LLC demonstrated an allegedly infringing medical device at a 5-day trade show in the District of Columbia. Other than conducting the demonstration, C Change Surgical had no contacts with the District of Columbia and did no business there. To obtain personal jurisdiction under DC's long-arm statute, plaintiff Medical Solutions, Inc. attempted to show that C Change's demonstrations at the trade show constituted a "use" under 35 U.S.C. § 271(a). But the evidence failed to reveal that the allegedly infringing device practiced all of the elements of any claim.

Thus, because the allegedly infringing device was not "put into action or service" sufficient to constitute "use" under the patent laws, there was no basis to invoke the District of Columbia's long-arm statute, and therefore the Federal Circuit affirmed the trial court's dismissal for lack of personal jurisdiction.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...